8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2019

 

 

Five Prime Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36070   26-0038620

(state or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

111 Oyster Point Boulevard

South San Francisco, California

  94080
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (415) 365-5600

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share   FPRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 7, 2019, Sheila Gujrathi, M.D. notified Five Prime Therapeutics, Inc. (“FivePrime”) of her decision to resign from the Board of Directors of FivePrime (the “Board”), effective immediately. Dr. Gujrathi’s resignation from the Board is not due to any disagreement with FivePrime on any matter relating to FivePrime’s operations, policies or practices.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

FivePrime held its annual meeting of stockholders (the “Annual Meeting”) on June 7, 2019. The final results for each of the proposals submitted to a vote of FivePrime’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in FivePrime’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2019 (the “Proxy Statement”).

Proposal 1: FivePrime’s stockholders elected all of the nominees for director to serve a three-year term until FivePrime’s 2022 annual meeting of stockholders, or until their respective successors are duly elected and qualified, by the votes set forth in the table below:

 

Nominee

   For        Withheld        Broker Non-Votes  

Franklin M. Berger, CFA

     17,756,803          13,221,892          3,220,247      

William Ringo

     30,712,961          265,734          3,220,247      

Lewis T. Williams, M.D., Ph.D.

     29,734,761          1,243,934          3,220,247      

Proposal 2: FivePrime’s stockholders approved, on an advisory basis, the compensation paid to FivePrime’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

28,419,520

   2,523,238    35,937    3,220,247

Proposal 3: FivePrime’s stockholders ratified the appointment of Ernst & Young LLP as FivePrime’s independent registered public accounting firm for the fiscal year ending December 31, 2019 by the votes set forth in the table below:

 

For

  

Against

  

Abstain

34,079,839

   86,341    32,762

Proposal 4: FivePrime’s stockholders approved the stock option exchange program, as disclosed in the Proxy Statement, by the votes set forth in the table below:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

20,121,058

   10,830,934    26,703    3,220,247


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Five Prime Therapeutics, Inc.
By:     /s/ Francis Sarena
  Francis Sarena
  Chief Strategy Officer and Secretary

Dated: June 10, 2019